Micro-fluidic chip, system and method for drug resistance evolution of bacteria
Patent Information
- Application Number
- CN202411031888.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-12
Smart Images

Figure CN118931691A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a microfluidic chip, system and method for bacterial drug resistance evolution. Background Art
[0002] This section merely provides background information related to the present disclosure and is not necessarily prior art.
[0003] Bacterial resistance to antibiotics has become one of the most serious threats to global public health. Generally speaking, antibiotic resistance can evolve through the continuous accumulation of multiple mutations. Adaptive laboratory evolution (ALE) is a basic method to study the potential adaptive mechanisms of microorganisms to adapt to antibiotic environments. The process of selecting resistant variants by multiplying bacterial populations with gradually increasing antibiotic concentrations is called resistance evolution selection of microorganisms.
[0004] The current drug-resistant evolution schemes include the continuous passaging method and the gradient method. The continuous passaging method is to continuously pass bacteria in a culture medium containing antibiotics. Every few generations or days, the antibiotic concentration in the culture medium is gradually increased, and by continuously applying selection pressure, resistant strains are eventually induced. The gradient method is to inoculate bacteria in a culture medium containing an antibiotic concentration gradient, and transfer the bacteria from the highest concentration antibiotic culture medium with bacterial growth to a higher concentration gradient antibiotic culture medium every other day, and finally screen for resistant strains. The above schemes last for a long time, require a large number of manual operation steps, are time-consuming and labor-intensive, and have low efficiency. At the same time, they consume culture medium and antibiotics, resulting in high costs. Summary of the invention
[0005] The purpose of the present invention is to at least solve the problem that a large number of manual operation steps lead to low efficiency and high cost due to consumption of culture medium and antibiotics in the current drug resistance evolution screening. This purpose is achieved by the following technical solutions:
[0006] The first aspect of the present invention provides a microfluidic chip for bacterial drug resistance evolution, comprising:
[0007] substrate;
[0008] A microchannel structure is arranged on the substrate, and the microchannel structure includes a concentration gradient grading module and multiple groups of semi-open microporous units connected in parallel and arranged in a matrix. The concentration gradient grading module includes a multi-stage microfluidic channel group, and each stage of the microfluidic channel group includes multiple mixing channels. Along the fluid flow direction, each stage of the microfluidic channel group adds one mixing channel compared with the microfluidic channel group of the previous stage. Each mixing channel of the microfluidic channel group of the last stage is respectively connected to a group of semi-open microporous units, and each group of semi-open microporous units includes multiple semi-open micropores, and the semi-open micropores have an open end away from the substrate.
[0009] The microfluidic chip for bacterial drug resistance evolution of the present invention is provided with a concentration gradient grading module and multiple groups of semi-open microporous units connected in parallel and arranged in a matrix. The concentration gradient grading module includes a multi-stage microfluidic channel group, and each mixing channel of the microfluidic channel group is respectively connected to a group of semi-open microporous units. When performing drug resistance evolution screening, the microfluidic chip for bacterial drug resistance evolution can simultaneously generate a series of antibiotic combinations with different concentration gradients, reduce manual operation steps, improve efficiency, and have less demand for the use of antibiotics and consumables, effectively reducing costs; at the same time, the semi-open design can also facilitate flexible and convenient sampling during the culture process, and has the advantages of high throughput, low cost, and convenient and quick operation.
[0010] In addition, the microfluidic chip for bacterial drug resistance evolution according to the present invention may also have the following additional technical features:
[0011] In some embodiments of the present invention, the concentration gradient grading module also includes a first connecting channel, the inlet end of the first connecting channel is connected and communicated with the outlet end of the microchannel group of the previous level, and the outlet end of the first connecting channel is connected and communicated with the inlet end of the microchannel group of the next level.
[0012] In some embodiments of the present invention, each of the mixing channels has the same length and extends in a serpentine shape.
[0013] In some embodiments of the present invention, the microchannel structure also includes at least two liquid inlet channels, and the two liquid inlet channels are both arranged at one end of the multi-level microfluidic channel group away from the multiple groups of semi-open microporous units, and are connected and communicated with the first-level microfluidic channel group, and one end of the two liquid inlet channels is provided with a liquid inlet.
[0014] In some embodiments of the present invention, the microchannel structure also includes a second connecting channel, which is arranged between the two liquid inlet channels and the first-level microchannel group, the inlet end of the second connecting channel is connected and communicated with the outlet ends of at least two of the liquid inlet channels, and the outlet end of the second connecting channel is connected and communicated with the inlet end of the first-level microchannel group.
[0015] In some embodiments of the present invention, the microchannel structure further includes a plurality of branch flow channels connected in parallel, each group of the semi-open microporous units corresponds to one branch flow channel, the inlet end of each branch flow channel is connected and communicated with the outlet end of the corresponding mixing flow channel, and the outlet end of each branch flow channel is connected and communicated with the inlet end of each semi-open micropore;
[0016] Each of the branch flow channels has the same length and is arranged parallel to each other.
[0017] In some embodiments of the present invention, the microchannel structure also includes a third connecting flow channel, and the third connecting flow channel is arranged between each of the branch flow channels and each of the semi-open micropores. Along the fluid flow direction, the length of each of the third connecting flow channels on the same branch flow channel is longer than the last third connecting flow channel.
[0018] In some embodiments of the present invention, each of the semi-open micropores includes a first micropore and a second micropore, the first micropore is connected and communicated with the second micropore, and the diameter of the first micropore is greater than the diameter of the second micropore;
[0019] The second micropore is connected to and communicates with the branch flow channel.
[0020] Another aspect of the present invention proposes a system for bacterial resistance evolution, comprising a collection device and a microfluidic chip for bacterial resistance evolution as described in any of the above items, the collection device comprising a collection rack, a collection orifice plate and an injection pump, the microfluidic chip and the collection orifice plate are arranged on the collection rack at intervals in the vertical direction, the injection pump is used to inject liquid into the microchannel structure, and the collection orifice plate is used to collect hanging drops dripping from the semi-open microwells.
[0021] The third aspect of the present invention provides a method for bacterial drug resistance evolution, wherein the method for bacterial drug resistance evolution utilizes the above-mentioned system for bacterial drug resistance evolution for cultivation, and the method for bacterial drug resistance evolution comprises the following steps:
[0022] After the microfluidic chip is sterilized, ethanol is introduced into the microchannel structure for infiltration treatment, and then bacterial culture solution is introduced to wash away the residual ethanol in the microchannel structure;
[0023] Using the injection pump, two liquid medicines are injected into one of the microfluidic chips simultaneously and separately, and a mixture of the two liquid medicines and the bacterial culture solution are injected into another microfluidic chip simultaneously and separately;
[0024] After the two microfluidic chips generate a stable concentration gradient, the bacterial sample is dripped into each of the semi-open microwells, and the two microfluidic chips are turned upside down on the upper layer of the collection rack, and the collection well plate is placed on the lower layer of the collection rack;
[0025] The collecting device and the microfluidic chip are placed in an incubator for culture, and the bacterial sample solution dripping from the semi-open microwells is collected through the collecting well plate. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Various other advantages and benefits will become apparent to those of ordinary skill in the art by reading the detailed description of the preferred embodiments below. The accompanying drawings are only for the purpose of illustrating the preferred embodiments and are not to be considered as limiting the present invention. Moreover, the same reference numerals are used throughout the accompanying drawings to represent the same components. In the accompanying drawings:
[0027] Figure 1 The schematic diagram of the structure of the microfluidic chip for bacterial drug resistance evolution according to an embodiment of the present invention is schematically shown;
[0028] Figure 2 A schematic diagram of a part of the structure of a microfluidic chip for bacterial drug resistance evolution according to an embodiment of the present invention is schematically shown;
[0029] Figure 3 for Figure 2 The enlarged view of point A in the middle;
[0030] Figure 4 The structure diagram of the system for evolving bacterial drug resistance according to an embodiment of the present invention is schematically shown;
[0031] Figure 5 The flowchart of the method for evolving bacterial drug resistance according to an embodiment of the present invention is schematically shown;
[0032] Figure 6 The concentration of the bacterial drug resistance evolution using the method for bacterial drug resistance evolution according to the embodiment of the present invention is schematically shown. Figure 1 ;
[0033] Figure 7 The concentration of the bacterial drug resistance evolution using the method for bacterial drug resistance evolution according to the embodiment of the present invention is schematically shown. Figure 2 .
[0034] The reference numerals are as follows:
[0035] 1. substrate; 10. first substrate; 11. second substrate; 110. through hole;
[0036] 2. Concentration gradient classification module; 20. First microchannel group; 200. First mixing channel; 21. Second microchannel group; 210. Second mixing channel; 22. Third microchannel group; 220. Third mixing channel; 23. Fourth microchannel group; 230. Fourth mixing channel; 24. First connecting channel;
[0037] 3. Branch flow channel;
[0038] 4. semi-open micropore unit; 40. semi-open micropore; 400. first micropore; 401. second micropore; 41. connecting channel; 42. third connecting flow channel;
[0039] 5. liquid inlet channel; 50. liquid inlet; 51. second connecting flow channel;
[0040] 60. Collection rack; 600. First plate; 601. Second plate; 602. Third plate; 61. Collection orifice plate. DETAILED DESCRIPTION
[0041] The exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. Although the exemplary embodiments of the present disclosure are shown in the accompanying drawings, it should be understood that the present disclosure can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present disclosure and to fully convey the scope of the present disclosure to those skilled in the art.
[0042] It should be understood that the terms used herein are only for the purpose of describing specific example embodiments and are not intended to be limiting. Unless the context clearly indicates otherwise, the singular forms "one", "an" and "said" as used herein may also be meant to include plural forms. The terms "include", "comprise", "contain", and "have" are inclusive, and therefore specify the existence of stated features, steps, operations, elements and / or parts, but do not exclude the existence or addition of one or more other features, steps, operations, elements, parts, and / or combinations thereof. The method steps, processes, and operations described herein are not interpreted as necessarily requiring them to be performed in the specific order described or illustrated, unless the execution order is clearly indicated. It should also be understood that additional or alternative steps may be used.
[0043] Although the terms first, second, third, etc. can be used in the text to describe multiple elements, components, regions, layers and / or sections, these elements, components, regions, layers and / or sections should not be limited by these terms. These terms can only be used to distinguish an element, component, region, layer or section from another region, layer or section. Unless the context clearly indicates, terms such as "first", "second" and other numerical terms do not imply order or sequence when used in the text. Therefore, the first element, component, region, layer or section discussed below can be referred to as the second element, component, region, layer or section without departing from the teaching of the example embodiments.
[0044] For ease of description, spatial relative terms may be used herein to describe the relationship of one element or feature relative to another element or feature as shown in the figure, such as "inside", "outside", "inner side", "outer side", "below", "below", "above", "above", etc. Such spatial relative terms are intended to include different orientations of the device in use or operation in addition to the orientation depicted in the figure. For example, if the device in the figure is turned over, then the elements described as "below other elements or features" or "below other elements or features" will subsequently be oriented as "above other elements or features" or "above other elements or features". Therefore, the example term "below..." can include both above and below orientations.
[0045] The drug-resistant evolution schemes of related technologies include continuous passage method and gradient method. The continuous passage method is to continuously pass bacteria in a culture medium containing antibiotics, and gradually increase the antibiotic concentration in the culture medium every few generations or days. By continuously applying selection pressure, drug-resistant strains are finally induced. The gradient method is to inoculate bacteria in a culture medium containing an antibiotic concentration gradient, and transfer from the highest concentration antibiotic culture medium with bacterial growth to a higher concentration gradient antibiotic culture medium every other day, and finally screen out drug-resistant strains. However, the drug-resistant evolution experiment requires at least 3-8 repeated experiments, and the short-term drug-resistant evolution needs to last for at least one week, requiring a large number of manual operation steps, and the combination of double or triple drugs to screen drug-resistant bacteria will be more time-consuming and labor-intensive, with low efficiency, and consume culture medium and antibiotics, resulting in high costs. The high-throughput pipetting workstation is an automated, multifunctional high-throughput liquid handling platform that can accelerate and simplify the drug-resistant evolution screening process. However, it usually requires complex software control, expensive equipment, and maintenance by professional engineers, which hinders their widespread use in ordinary microbiology laboratories.
[0046] In view of this, the present embodiment provides a microfluidic chip for bacterial resistance evolution, which aims to simultaneously generate a series of antibiotic combinations with different concentration gradients by setting a concentration gradient grading module 2 and a plurality of groups of semi-open microporous units 4 connected in parallel and arranged in a matrix, thereby reducing manual operation steps and reducing costs, thereby solving the above technical problems.
[0047] like Figures 1 to 4As shown, according to an embodiment of the present invention, a microfluidic chip for bacterial resistance evolution is proposed, the microfluidic chip for bacterial resistance evolution includes a substrate 1 and a microchannel structure, the microchannel structure is arranged on the substrate 1, the microchannel structure includes a concentration gradient grading module 2 and a plurality of groups of semi-open microporous units 4 connected in parallel and arranged in a matrix, the substrate 1 includes a first substrate 10 and a second substrate 11, the microchannel structure is opened on the first substrate 10, and has a certain depth, the second substrate 11 is arranged on the first substrate 10, and a through hole 110 is opened on the second substrate 11 at a position corresponding to the semi-open microporous unit 4, which can avoid the position of the semi-open microporous unit 4, so that the end of the microporous unit away from the first substrate 10 is an open structure, and the rest of the second substrate 11 is overlapped with the first substrate 10 to form a closed structure. The concentration gradient grading module 2 includes a multi-stage microfluidic channel group, each stage of the microfluidic channel group includes a plurality of mixing channels. Along the fluid flow direction, each stage of the microfluidic channel group adds a mixing channel compared with the previous stage of the microfluidic channel group. Each mixing channel of the last stage of the microfluidic channel group is respectively connected to a group of semi-open microporous units 4. Each group of semi-open microporous units 4 includes a plurality of semi-open micropores 40. When culturing bacteria, the microfluidic chip needs to be inverted as a whole so that the open end of the semi-open micropore 40 structure is vertically downward, so that the droplets saturated with bacterial growth in the micropores drip regularly, thereby continuously renewing the oxygen and nutrients around the bacteria, thereby realizing continuous bacterial propagation and maintaining a constant concentration of antibiotic exposure.
[0048] The microfluidic chip for bacterial drug resistance evolution of the present invention is provided with a concentration gradient grading module 2 and a plurality of groups of semi-open microporous units 4 connected in parallel and arranged in a matrix. The concentration gradient grading module 2 includes a multi-stage microfluidic channel group, and each mixing channel of the microfluidic channel group is respectively connected to a group of semi-open microporous units 4. When performing drug resistance evolution screening, the microfluidic chip for bacterial drug resistance evolution can simultaneously generate a series of antibiotic combinations with different concentration gradients, reduce manual operation steps, improve efficiency, and require less use of antibiotics and consumables, effectively reducing costs. At the same time, the semi-open design can also facilitate flexible and convenient sampling during the culture process, and has the advantages of high throughput, low cost, and convenient and quick operation.
[0049] In some embodiments of the present invention, the concentration gradient grading module 2 also includes a first connecting channel 24, the inlet end of the first connecting channel 24 is connected and communicated with the outlet end of the upper microfluidic channel group, and the outlet end of the first connecting channel 24 is connected and communicated with the inlet end of the next microfluidic channel group. In this embodiment, the concentration gradient grading module 2 includes four microfluidic channel groups, namely the first microfluidic channel group 20, the second microfluidic channel group 21, the third microfluidic channel group 22 and the fourth microfluidic channel group 23. The first microfluidic channel group 20 includes three first mixing channels 200 in parallel. The three first mixing channels 200 are spaced apart along the length direction of the first connecting channel 24 and are connected and communicated with the first connecting channel 24. The above three first mixing channels 200 have the same length and extend in a serpentine shape. The second microchannel group 21 includes four parallel second mixing channels 210, which are arranged at intervals along the length direction of the first connecting channel 24 and are connected and communicated with the first connecting channel 24. Similarly, the above four second mixing channels 210 have the same length and extend in a serpentine shape. Similarly, the third microchannel group 22 includes five parallel third mixing channels 220, and the fourth microchannel group 23 includes six parallel fourth mixing channels 230. The three first mixing channels 200 and the four second mixing channels 210, the four second mixing channels 210 and the five third mixing channels 220, and the five third mixing channels 220 and the six fourth mixing channels 230 are all connected and communicated through the above first connecting channels 24, and the first connecting channels 24 between each level of microchannel groups are arranged in parallel with each other. The depth of the above-mentioned first mixing channel 200, second mixing channel 210, third mixing channel 220, fourth mixing channel 230 and first connecting channel 24 is 0.2mm-0.4mm (for example, 0.2mm or 0.3mm or 0.4mm or any value in the range of 0.2mm-0.4mm), and the width is 0.4mm-0.8mm (for example, 0.4mm or 0.5mm or 0.6mm or 0.8mm or any value in the range of 0.4mm-0.8mm).
[0050] In other embodiments, the concentration gradient classification module 2 can also be configured to include two-stage microfluidic channel groups, three-stage microfluidic channel groups, or five-stage microfluidic channel groups according to actual experimental requirements, and the number of mixing channels included in each microfluidic channel group can also be increased or decreased.
[0051] In other embodiments, the first mixing channel 200 , the second mixing channel 210 , the third mixing channel 220 , and the fourth mixing channel 230 may also be configured as U-shaped, bow-shaped, or spiral channels.
[0052] In some embodiments of the present invention, the microchannel structure further includes a plurality of branch channels 3 connected in parallel, each group of semi-open microporous units 4 corresponds to a branch channel 3, the inlet end of each branch channel 3 is connected and communicated with the outlet end of the corresponding mixing channel, and the outlet end of each branch channel 3 is connected and communicated with the inlet end of each semi-open micropore 40; each branch channel 3 has the same length and is arranged in parallel with each other. In this embodiment, the number of branch channels 3 is six, and the six branch channels 3 are connected and communicated with the six fourth mixing channels 230 in a one-to-one correspondence, and the six branch channels 3 are arranged in parallel with each other and have the same length. The width of each branch channel 3 is 0.2mm-0.4mm (for example, 0.2mm or 0.3mm or 0.4mm or any value in the range of 0.2mm-0.4mm), and the length is 42mm. There are six groups of semi-open microporous units 4, which are connected and communicated with the six branch channels 3 one by one. Each group of semi-open microporous units 4 includes five semi-open micropores 40, which are spaced apart along the length direction of the branch channel 3.
[0053] Each semi-open micropore 40 includes a first micropore 400 and a second micropore 401, the first micropore 400 is connected and communicated with the second micropore 401, the diameter of the first micropore 400 is greater than the diameter of the second micropore 401, wherein the diameter of the first micropore 400 is 3.0 mm-3.4 mm (for example, 3.0 mm or 3.1 mm or 3.2 mm or 3.4 mm or any value in the range of 3.0 mm-3.4 mm), the diameter of the second micropore 401 is 2.2 mm-2.6 mm (for example, 2.2 mm or 2.3 mm or 2.5 mm or 2.6 mm or any value in the range of 2.2 mm-2.6 mm), and the diameter of the first micropore 400 is 3.0 mm-3.4 mm (for example, 3.0 mm or 3.1 mm or 3.2 mm or 3.4 mm or any value in the range of 3.0 mm-3.4 mm). The hole 400 is connected to the second micropore 401 through a connecting channel 41, the width of the connecting channel 41 is 0.2mm-0.4mm (for example, 0.2mm or 0.3mm or 0.4mm or any value in the range of 0.2mm-0.4mm), the depth is 1.6mm-2.0mm (for example, 1.6mm or 1.8mm or 2.0mm or any value in the range of 1.6mm-2.0mm), and the center distance between the first micropore 400 and the second micropore 401 is 4.0mm-5.5mm (for example, 4.0mm or 4.5mm or 5.5mm or any value in the range of 4.0mm-5.5mm).
[0054] In this embodiment, the diameter of the first micropore 400 is preferably 3.0 mm, the diameter of the second micropore 401 is preferably 2.6 mm, the width of the connecting channel 41 is preferably 0.2 mm, the depth is preferably 1.6 mm, and the center distance between the first micropore 400 and the second micropore 401 is preferably 4.2 mm.
[0055] In other embodiments, the number of the semi-open micropores 40 in each group of semi-open micropore units 4 may also be three, six, eight, etc. In addition, the arrangement of the semi-open micropore units 4 may also be set to other forms according to actual needs.
[0056] In this embodiment, the second micropore 401 is connected and communicated with the branch channel 3. This is because when performing bacterial resistance evolution screening, liquid is injected into the semi-open micropore 40 through the branch channel 3. The liquid in the branch channel 3 is first injected into the second micropore 401 with a smaller diameter. The weight of the liquid in the second micropore 401 with a smaller diameter is smaller, so that the liquid in the second micropore 401 is not easy to drip, so that the liquid in the second micropore 401 flows through the connecting channel 41 to the first micropore 400 connected to the second micropore 401. Therefore, the second micropore 401 can be used for the formation of a bacterial hanging drop array. Since the first micropore 400 has a larger diameter and a larger weight of the liquid in the first micropore 400, the liquid in the first micropore 400 is easier to drip than the first micropore 400, so that it can be used to replace the hanging drop medium in the semi-open micropore 40, and the gas-liquid interface at the bottom of the bacterial droplet can prevent the bacteria from adhering to the chip, while keeping the bacteria in a relatively oxygen-rich state, thereby achieving efficient bacterial growth. In addition, the paired design of the large-diameter first micropore 400 and the small-diameter second micropore 401 and the semi-arc shape of the bottom of the hanging drop can also reduce the force of the flowing culture fluid on the bacteria. The force here mainly refers to the horizontal shear force of the fluid on the bacteria, making it difficult for biofilm to form at the bottom of the hanging drop, which is conducive to the efficient growth of bacteria and improves the growth efficiency of bacteria.
[0057] In the embodiment, a first annular protrusion (not shown in the figure) is arranged along the circumference on the end surface of the open end of the first micropore 400, and a second annular protrusion (not shown in the figure) is arranged along the circumference on the end surface of the open end of the second micropore 401. Specifically, the first annular protrusion is arranged on the end surface of the open end of the first micropore 400, and extends to the end away from the first substrate 10, and the second annular protrusion is arranged on the end surface of the open end of the second micropore 401, and extends to the end away from the first substrate 10. By arranging the first annular protrusion and the second annular protrusion, it is not easy for droplets placed in the first micropore 400 and the second micropore 401 to overflow, and a relatively stable hanging droplet can be formed to prevent the occurrence of droplet fusion or droplet crosstalk.
[0058] In some embodiments of the present invention, the microchannel structure further includes a third connecting channel 42, and a third connecting channel 42 is provided between each branch channel 3 and each semi-open micropore 40. Along the fluid flow direction, the length of each third connecting channel 42 on the same branch channel 3 is increased compared with the last third connecting channel 42. Specifically, one end of the third connecting channel 42 is connected and communicated with the branch channel 3, and the other end of the third connecting channel 42 is connected and communicated with the second micropore 401. Except for the semi-open micropore 40 at the end of each branch channel 3, each third connecting channel 42 extends in a serpentine shape. The serpentine third connecting channel 42 can increase the flow distance of the liquid, ensuring that when the liquid flowing out of the fourth mixing channel 230 flows to each second micropore 401 through the branch channel 3, the distance to each second micropore 401 is the same.
[0059] In some embodiments of the present invention, the microchannel structure further includes at least two liquid inlet channels 5, both of which are arranged at one end of the multi-stage microchannel group away from the multiple groups of semi-open microporous units 4, and are connected and communicated with the first-stage microchannel group, and one end of the two liquid inlet channels 5 is provided with a liquid inlet 50. Specifically, the liquid inlet channels 5 are arranged at intervals along the length direction of the first connecting channel 24, and the end of the liquid inlet channel 5 away from the semi-open microporous unit 4 is provided with a liquid inlet 50. The microchannel structure further includes a second connecting channel 51, which is arranged between the two liquid inlet channels 5 and the first-stage microchannel group, and the inlet end of the second connecting channel 51 is connected and communicated with the outlet ends of the two liquid inlet channels 5, and the outlet end of the second connecting channel 51 is connected and communicated with the inlet ends of the three first mixing channels 200. When performing drug resistance evolution screening, both liquid inlets 50 are connected to an injection device, for example, an injection pump or other device is used to inject the experimental drug solution into the liquid inlet channel 5, and the experimental drug solution passes through the concentration gradient classification module 2 to form six columns of concentration gradients and flows into the semi-open micropores 40 through the branch flow channel 3. The closed channel structure can provide stable pressure input and continuous fluid delivery, thereby achieving the purpose of continuous flow of the bacterial culture medium in the microfluidic chip.
[0060] When the microfluidic chip for bacterial drug resistance evolution of this embodiment is processed, the mold of the microfluidic chip is first processed, and a microchannel structure with various depths is pre-processed on the PMMA mold by machining and cutting polymethyl methacrylate (PMMA). After the mold processing is completed, an organic composite of polydimethylsiloxane (PDMS) and a curing agent of 10:1 is poured on the PMMA mold, so that some of the microstructures with lower heights are completely covered by the organic composite layer, and some micro-column structures with higher heights may not be completely covered. Then cure in an oven at 80°C for 2h. After taking out the cured PDMS chip, two holes at the liquid inlet 50 are punched on the cured PDMS chip. Finally, take the glass (i.e., the second substrate 11 in the previous text) and cover it on the top of the cured PDMS chip (i.e., the first substrate 10 in the previous text), and both are modified with oxygen plasma for 25s, and the two are pressed together to complete the production of the microfluidic chip for bacterial drug resistance evolution. The above-mentioned closed concentration gradient grading module 2, liquid inlet channel 5, branch channel 3, first connecting channel 24, second connecting channel 51 and third connecting channel 42 are formed between the top surface of the first substrate 10 and the bottom surface of the second substrate 11.
[0061] The second aspect of the present invention provides a system for evolving bacterial resistance. Figure 4As shown, it includes a collecting device and the above-mentioned microfluidic chip for bacterial drug resistance evolution, the collecting device includes a collecting rack 60, a collecting orifice plate 61 and an injection pump, the microfluidic chip and the collecting orifice plate 61 are arranged on the collecting rack 60 at intervals in the vertical direction, the injection pump is used to inject liquid into the microchannel structure, and the collecting orifice plate 61 is used to collect the hanging drops dripping from the semi-open micropores 40. Specifically, the collecting rack 60 includes a first plate body 600, a second plate body 601 and a third plate body 602 connected in sequence from top to bottom, the first plate body 600, the second plate body 601 and the third plate body 602 enclose a three-layer rectangular frame structure, the top surface of the first plate body 600 is the first layer of the collecting rack 60, the second plate body 601 and the first plate body 600 are between the second layer, and the third plate body 602 and the second plate body 601 are between the third layer. The collection orifice plate 61 is placed on the third layer, specifically on the top surface of the third plate body 602. The collection orifice plate 61 is provided with a plurality of collection holes arranged in a matrix. The positions of the collection holes of the collection orifice plate 61 can be adapted to the positions of the semi-open micropores 40 of the microfluidic chip, so that the hanging drops dripping from the microfluidic chip can just drip into the collection holes for collection. The first plate body 600 is provided with at least one rectangular opening. When the microfluidic chip is placed on the top surface of the first plate body 600, the rectangular opening can avoid the plurality of semi-open micropores 40 of the microfluidic chip, so that the liquid in the semi-open micropores 40 drips downward into the collection holes. The second plate body 601 is provided with an opening, which is a visual window area, which is convenient for observing the situation of the collection orifice plate 61 below and for experimental operation. In this embodiment, when conducting drug resistance evolution of bacteria, the number of microfluidic chips is two, two rectangular openings are set on the first plate body 600, the collecting well plate 61 is a 96-well plate, and the two microfluidic chips are placed on the top surface of the first plate body 600 and correspond to the positions of the rectangular openings respectively. The collecting holes of the collecting well plate 61 are placed corresponding to the first micropore 400 of the semi-open micropore 40, and then the liquid is continuously injected into the microfluidic chip through the injection pump, and the hanging drops are regularly dripped through the first micropore 400 as the outlet, and the dripping liquid is collected through the collecting well plate 61.
[0062] The above-mentioned system for the evolution of bacterial resistance can allow two microfluidic chips to work simultaneously by setting up a collection device used in conjunction with a microfluidic chip, and can generate 12 concentration combinations and 60 hanging drops at the same time, so as to quickly and conveniently realize the recovery of bacterial samples with high-throughput hanging drops. Every time the concentration of antibiotics injected into the microfluidic chip needs to be changed, the 96-well plate at the bottom of the bacterial sample collection device rack is taken out and stored for subsequent analysis, and a new 96-well plate is inserted. The above-mentioned system for the evolution of bacterial resistance is low-cost, easy to operate, can be sampled in real time, and does not require liquid replacement operations, so as to realize high-throughput and rapid bacterial resistance evolution.
[0063] The third aspect of the present invention provides a method for evolving bacterial resistance, see Figure 5As shown, the system for bacterial drug resistance evolution of the second aspect is used for culturing, and the method for bacterial drug resistance evolution comprises the following steps:
[0064] Step 1: After the microfluidic chip is sterilized, ethanol is introduced into the microchannel structure for infiltration treatment, and then bacterial culture solution is introduced to wash the residual ethanol in the microchannel structure. Specifically, both microfluidic chips are sterilized by high temperature and high pressure, and the injection pump is connected to the liquid inlet 50 of the microfluidic chip through the injection tube, and 75% ethanol is introduced into the microfluidic chip through the injection pump to infiltrate the chip for 5 minutes, and then bacterial LB broth culture solution is introduced for 10 minutes to wash the residual ethanol in the microfluidic chip.
[0065] Step 2: Use an injection pump to simultaneously and separately inject two kinds of liquid medicine into one of the microfluidic chips, and simultaneously and separately inject a mixture of the two liquid medicines and a bacterial culture solution into the other microfluidic chip. Specifically, the two chips work simultaneously, and one microfluidic chip is for double-drug injection on the opposite sides, that is, two kinds of liquid medicines A and B are injected simultaneously and separately through two injection ports. In the present embodiment, liquid medicine A is ceftazidime / avibactam, and liquid medicine B is polymyxin B. In other embodiments, liquid medicines A and B can be replaced according to experimental requirements. The other is double-drug injection on the same side, that is, a mixture of the above-mentioned two liquid medicines A and B and a bacterial culture solution are injected simultaneously and separately through two injection ports. The single-sided injection flow rate is 15 μL / min, and the total flow rate in the chip is 30 μL / min. By injecting liquid using the above-mentioned injection method, 12 concentration combinations and 60 hanging drops can be generated simultaneously. See. Figure 6 and 7 , Figure 6 To use the method for bacterial resistance evolution to perform double drug injection on the opposite side of the concentration map of bacterial resistance evolution, Figure 7 The concentration diagram of bacterial resistance evolution by injecting two drugs on the same side using the method for bacterial resistance evolution includes a drug-free control, a single drug control, a two-drug equal-ratio concentration mixture, and a two-drug unequal-ratio concentration mixture. The drug-free control is Figure 7 The top five semi-open microwells 40 in the microfluidic chip in the single drug control are Figure 6 The top and bottom rows of the microfluidic chip have 10 semi-open microwells 40, and the two drugs are mixed in equal concentrations. Figure 7 In the microfluidic chip, except for the top five semi-open micropores 40, the remaining 25 semi-open micropores 40 are mixed with two drugs at different concentration ratios. Figure 6 For the remaining 20 semi-open microwells 40 except for the 10 semi-open microwells 40 in the uppermost and lowermost rows, there are 5 replicates for each of the above conditions.
[0066] Step 3: After the two microfluidic chips generate a stable concentration gradient, the bacterial sample is dripped into each semi-open microwell 40, and the two microfluidic chips are turned upside down on the upper layer of the collection rack 60, and the collection well plate 61 is placed on the lower layer of the collection rack 60. Specifically, after the concentration is stabilized, the bacterial sample solution of a specific density is dripped into the bacterial culture wells of the microfluidic chip by a pipette, and then the two microfluidic chips are turned 180 degrees and placed on the top surface of the first plate body 600 and respectively correspond to the positions of the rectangular openings, and the collection wells of the collection well plate 61 are placed corresponding to the first microwells 400 of the semi-open microwells 40.
[0067] Step 4: Place the collection device and the microfluidic chip in an incubator for incubation, and collect the bacterial sample solution dripping from the semi-open micropores 40 through the collection well plate 61. Specifically, place the above-mentioned collection device, microfluidic chip and culture dish in a 37°C incubator for incubation and culture. After the bacterial reproduction generation reaches the target requirement, take out the 96-well plate, and use a pipette to absorb the bacterial sample solution in the collection well plate for subsequent experimental research or analysis.
[0068] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims
1. A microfluidic chip for bacterial drug resistance evolution, characterized in that: include: substrate; A microchannel structure is arranged on the substrate, and the microchannel structure includes a concentration gradient grading module and multiple groups of semi-open microporous units connected in parallel and arranged in a matrix. The concentration gradient grading module includes a multi-stage microfluidic channel group, and each stage of the microfluidic channel group includes multiple mixing channels. Along the fluid flow direction, each stage of the microfluidic channel group adds one mixing channel compared with the microfluidic channel group of the previous stage. Each mixing channel of the microfluidic channel group of the last stage is respectively connected to a group of semi-open microporous units, and each group of semi-open microporous units includes multiple semi-open micropores, and the semi-open micropores have an open end away from the substrate.
2. The microfluidic chip for bacterial drug resistance evolution according to claim 1, characterized in that: The concentration gradient classification module also includes a first connecting channel, the inlet end of the first connecting channel is connected and communicated with the outlet end of the microchannel group of the previous level, and the outlet end of the first connecting channel is connected and communicated with the inlet end of the microchannel group of the next level.
3. The microfluidic chip for bacterial drug resistance evolution according to claim 1, characterized in that: Each of the mixing flow channels has the same length and extends in a serpentine shape.
4. The microfluidic chip for bacterial drug resistance evolution according to claim 1, characterized in that: The microchannel structure also includes at least two liquid inlet channels, which are both arranged at one end of the multi-level microfluidic channel group away from the multiple groups of semi-open microporous units, and are connected and communicated with the first-level microfluidic channel group, and one end of the two liquid inlet channels is provided with a liquid inlet.
5. The microfluidic chip for bacterial drug resistance evolution according to claim 4, characterized in that: The microchannel structure also includes a second connecting flow channel, which is arranged between the two liquid inlet channels and the first-level microchannel group, the inlet end of the second connecting flow channel is connected and communicated with the outlet ends of at least two of the liquid inlet channels, and the outlet end of the second connecting flow channel is connected and communicated with the inlet end of the first-level microchannel group.
6. The microfluidic chip for bacterial drug resistance evolution according to claim 1, characterized in that: The microchannel structure further comprises a plurality of branch flow channels connected in parallel, each group of the semi-open microporous units corresponds to one branch flow channel, the inlet end of each branch flow channel is connected and communicated with the outlet end of the mixing flow channel corresponding thereto, and the outlet end of each branch flow channel is connected and communicated with the inlet end of each semi-open micropore; Each of the branch flow channels has the same length and is arranged parallel to each other.
7. The microfluidic chip for bacterial drug resistance evolution according to claim 6, characterized in that: The microchannel structure also includes a third connecting flow channel, and the third connecting flow channel is arranged between each branch flow channel and each semi-open micropore. Along the fluid flow direction, the length of each third connecting flow channel on the same branch flow channel is longer than the last third connecting flow channel.
8. The microfluidic chip for bacterial drug resistance evolution according to claim 6, characterized in that: Each of the semi-open micropores includes a first micropore and a second micropore, the first micropore is connected and communicated with the second micropore, and the diameter of the first micropore is larger than the diameter of the second micropore; The second micropore is connected and communicated with the branch flow channel.
9. A system for bacterial drug resistance evolution, characterized in that: It comprises a collecting device and a microfluidic chip for bacterial resistance evolution as described in any one of claims 1 to 8, wherein the collecting device comprises a collecting frame, a collecting orifice plate and an injection pump, the microfluidic chip and the collecting orifice plate are arranged on the collecting frame at intervals in the vertical direction, the injection pump is used to inject liquid into the microchannel structure, and the collecting orifice plate is used to collect hanging drops dripping from the semi-open microwells.
10. A method for evolving bacterial resistance, characterized in that: The method for bacterial drug resistance evolution is cultured using the system for bacterial drug resistance evolution as claimed in claim 9, and the method for bacterial drug resistance evolution comprises the following steps: After the microfluidic chip is sterilized, ethanol is introduced into the microchannel structure for infiltration treatment, and then bacterial culture solution is introduced to wash away the residual ethanol in the microchannel structure; Using the injection pump, two liquid medicines are injected into one of the microfluidic chips simultaneously and separately, and a mixture of the two liquid medicines and the bacterial culture solution are injected into another microfluidic chip simultaneously and separately; After the two microfluidic chips generate a stable concentration gradient, the bacterial sample is dripped into each of the semi-open microwells, and the two microfluidic chips are turned upside down on the upper layer of the collection rack, and the collection well plate is placed on the lower layer of the collection rack; The collecting device and the microfluidic chip are placed in an incubator for culture, and the bacterial sample solution dripping from the semi-open microwells is collected through the collecting well plate.
Citation Information
Patent Citations
Integrated microfluidic chip for screening medicine and method for applying integrated microfluidic chip
CN105080627A
Micro-fluidic chip as well as preparation method and applications thereof
CN105713834A
Concentration gradient and bacteria detection integrated micro-fluidic chip and design method thereof
CN113171807A
Microfluidic chip for bacterial culture, bacterial culture system and bacterial culture method
CN117965272A
Bacterial drug screening system and method
CN118956574A
